Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen.
about
Progress and problems in understanding and managing primary Epstein-Barr virus infectionsSerological diagnosis of Epstein-Barr virus infection: Problems and solutionsDetection of EBV-DNA in serum samples of an immunosuppressed child during a three years follow-up: association of clinical and PCR data with active infection.Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.Fluorescence in situ hybridization is superior for monitoring Epstein Barr viral load in infectious mononucleosis patients.Measurement of Epstein-Barr virus DNA load using a novel quantification standard containing two EBV DNA targets and SYBR Green I dyeCommutability of the Epstein-Barr virus WHO international standard across two quantitative PCR methods.Diagnostic testing in Epstein-Barr virus infection.Sulfated small molecules targeting eBV in Burkitt lymphoma: from in silico screening to the evidence of in vitro effect on viral episomal DNA.Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease.Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipientsCan Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma.Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders.Sequence Variation in Amplification Target Genes and Standards Influences Interlaboratory Comparison of BK Virus DNA Load Measurement.Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.Molecular approaches towards characterization, monitoring and targeting of viral-associated hematological malignancies.Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseasesQuantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients.Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation.Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR.Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients.Laboratory assays for Epstein-Barr virus-related disease.Sickle cell trait is not associated with endemic Burkitt lymphoma: an ethnicity and malaria endemicity-matched case-control study suggests factors controlling EBV may serve as a predictive biomarker for this pediatric cancerIncreased Epstein-Barr virus in breast milk occurs with subclinical mastitis and HIV shedding.Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.Epstein-Barr virus DNA as a biomarker for Epstein-Barr virus-positive lymphomas: are we there yet?Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.Determining EBV load: current best practice and future requirements.Epstein-Barr virus serology and PCR: conflicting results in an immunocompetent host. A case report and review of literature.Comparison of QIAsymphony automated and QIAamp manual DNA extraction systems for measuring Epstein-Barr virus DNA load in whole blood using real-time PCR.Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.Comparison of quantitative competitive PCR with LightCycler-based PCR for measuring Epstein-Barr virus DNA load in clinical specimensAsymptomatic primary infection with Epstein-Barr virus: observations on young adult cases.Solid phase DNA amplification: a simple Monte Carlo Lattice model.Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi.A fast and accurate method of detecting Aleutian mink disease virus in blood and tissues of chronically infected mink.
P2860
Q24597706-C1F8382B-7E4B-433C-8A5A-FC55822F5631Q26829346-B76D2CA9-3C8E-40FD-86A1-BF88A4BA760BQ30989314-EEE8C52E-B1F8-4166-9938-D9E0CA2A57A4Q33218405-6380FB77-363C-43DE-831E-01C3076CAFBDQ33634792-518EE099-C3F4-4A01-A03C-4060BF3BA560Q34217149-8FF8312B-DECC-4487-8A4F-1A6E4A87FC69Q34298224-A95BB8A1-3625-4D88-AAD5-1EE511F4B829Q34401554-BC782A29-7706-4A11-8865-1625B841B644Q34563797-4E842B22-A98F-400C-9925-26659F327975Q34769887-D7CAA7FC-96D9-4189-92BB-B9CE3DF3A510Q34946254-67D1CCD5-7CDE-4F2E-BC49-C3045C13DFF2Q35225987-79E23AD6-E3A7-4831-A56F-649A6F2CC459Q35619542-86C2E4F8-6A6E-48E4-A1DF-446DBC6DA7D2Q35766015-C7571A03-7EAF-4AA6-BD16-1568B18599B7Q36272592-F934048A-97D8-4FCD-B63A-FCE8B5CC79A8Q36297604-BB35174B-A088-41AF-B6A0-EC13E8BAF755Q36389306-D6D921A7-DAC5-40E6-82DE-F1A508AD156FQ36537637-E1F57A4C-3873-464E-AB4B-D8DD8BB430EDQ36670930-C049C67C-0A1D-40B3-930D-A52C7F1028B2Q36732580-7A483F70-F04B-40AE-8EE2-96AE543644BBQ36825808-38906C41-BA54-4D68-BAF1-7042A3A1F33CQ36945756-3EDBACD2-BF58-4760-9615-FB357BB70E66Q36957919-62FED13F-E01C-4476-9D5D-9CBC85AC77B3Q37058470-5D03008F-D789-4E02-A75E-2DED948F5970Q37152749-383001D5-BDD6-43FF-8282-A6C31F2B038DQ37192117-7B84E189-180F-4F37-AC95-4F0F7E660551Q37316016-AB743B20-E6D8-4453-932A-9D0A860E59DBQ37327918-6E019975-7DDA-423F-9105-F08963D7DC68Q37373656-E3B26494-1D13-4910-BEF0-20B34DBB5526Q37426438-7AA8B466-4A61-4C5D-AC7E-780DDEACFFAEQ37726624-1ECBFA30-F4F8-40D8-AF5D-279D3415BF3DQ38079834-F7F1583F-3D5F-4BAF-BC22-916DF155E374Q38219320-E6F7F53E-C279-437C-ABEE-3957BC93DCE9Q38714494-6CB08EBD-523F-477C-9BFD-2ACD326CC5DEQ38877813-D8B302FD-98DD-45FD-A458-42C3B70F7778Q39694961-6098FE3A-813D-4A79-9661-4C6FBF28C75DQ40073024-B36FAD94-3D55-43F9-9792-70D9FB02CD79Q40255319-92725C4D-124A-4622-87F1-33C96499B323Q40304324-69B9CB7F-4711-4958-B083-C62FEAC2A205Q40340331-0C799F47-4960-440C-95D1-EF458B406CA2
P2860
Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Toward standardization of Epst ...... s preferred clinical specimen.
@en
Toward standardization of Epst ...... s preferred clinical specimen.
@nl
type
label
Toward standardization of Epst ...... s preferred clinical specimen.
@en
Toward standardization of Epst ...... s preferred clinical specimen.
@nl
prefLabel
Toward standardization of Epst ...... s preferred clinical specimen.
@en
Toward standardization of Epst ...... s preferred clinical specimen.
@nl
P2860
P1476
Toward standardization of Epst ...... as preferred clinical specimen
@en
P2093
P2860
P304
P356
10.1128/JCM.39.4.1211-1216.2001
P407
P577
2001-04-01T00:00:00Z